AU2023400A - Compositions and methods for inhibiting angiogenesis using trna and fragments thereof - Google Patents

Compositions and methods for inhibiting angiogenesis using trna and fragments thereof

Info

Publication number
AU2023400A
AU2023400A AU20234/00A AU2023400A AU2023400A AU 2023400 A AU2023400 A AU 2023400A AU 20234/00 A AU20234/00 A AU 20234/00A AU 2023400 A AU2023400 A AU 2023400A AU 2023400 A AU2023400 A AU 2023400A
Authority
AU
Australia
Prior art keywords
trna
fragments
compositions
methods
inhibiting angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU20234/00A
Inventor
Krzystof Bojanowski
M. Judah Folkman
Yuen Shing
Hui Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Children s Medical Center Corp
Original Assignee
Children s Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10803698P priority Critical
Priority to US60108036 priority
Application filed by Children s Medical Center Corp filed Critical Children s Medical Center Corp
Priority to PCT/US1999/026696 priority patent/WO2000027340A2/en
Publication of AU2023400A publication Critical patent/AU2023400A/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
AU20234/00A 1998-11-12 1999-11-12 Compositions and methods for inhibiting angiogenesis using trna and fragments thereof Abandoned AU2023400A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10803698P true 1998-11-12 1998-11-12
US60108036 1998-11-12
PCT/US1999/026696 WO2000027340A2 (en) 1998-11-12 1999-11-12 USE OF t-RNA AND FRAGMENTS FOR INHIBITING ANGIOGENESIS AND COMPOSITIONS THEREOF

Publications (1)

Publication Number Publication Date
AU2023400A true AU2023400A (en) 2000-05-29

Family

ID=22319903

Family Applications (1)

Application Number Title Priority Date Filing Date
AU20234/00A Abandoned AU2023400A (en) 1998-11-12 1999-11-12 Compositions and methods for inhibiting angiogenesis using trna and fragments thereof

Country Status (2)

Country Link
AU (1) AU2023400A (en)
WO (1) WO2000027340A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1411954T3 (en) 2000-10-18 2011-03-14 Pharmasset Inc Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
EP1979364A4 (en) 2005-08-23 2010-10-27 Univ Pennsylvania Rna containing modified nucleosides and methods of use thereof
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857413A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2013090648A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US20150064235A1 (en) 2012-03-30 2015-03-05 Moderna Therapeutics, Inc. Modified polynucleotides
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015120022A1 (en) * 2014-02-04 2015-08-13 Thomas Jefferson University Specific expression of half-trna in cancers
WO2018119421A1 (en) * 2016-12-22 2018-06-28 Thomas Jefferson University Compositions and methods of using rna fragments

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2824411A1 (en) * 1978-06-03 1979-12-13 Boehringer Sohn Ingelheim Antiviral effective t-RNA preparations

Also Published As

Publication number Publication date
WO2000027340A9 (en) 2000-11-30
WO2000027340A3 (en) 2000-08-17
WO2000027340A2 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
AU770360C (en) Vaccine composition
EP1069887B8 (en) Aerosol composition
AU4903600A (en) An insulating construction form and manner of employment for same
AU4256299A (en) Novel mannanases
EP1073439A4 (en) Pharmaceutical composition
EP1109555A4 (en) Novel angiogenesis inhibitors
NZ514350A (en) Compositions and methods for effecting the levels of cholesterol
AU2001257526A1 (en) Splice-region antisense composition and method
SK11702000A3 (en) Pharmaceutical composition
EP1097147A4 (en) Novel angiogenesis inhibitors
AU2013599A (en) Intumescent composition and method
AU5300000A (en) Small-scale mill and method thereof
AU6106999A (en) Process
AU1543497A (en) Pharmaceutical compositions
ZA9901885B (en) Novel methods and compositions for delivery of taxanes.
AU7068600A (en) Encrypted coupons
AU2229899A (en) Insulated concrete form
HU9901606D0 (en) Pharmaceutical compositions
AU6111699A (en) Novel method and compounds
AU4003999A (en) Healthbar formulations
AU4677199A (en) Multibinding inhibitors of topoisomerase
AU6479999A (en) Fracture treatment
ZA9807536B (en) Stanol comprising compositions.
AU2548899A (en) Composition comprising theanine
AU5062099A (en) An antilipemic formulation

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase